Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin

Oliver A Cornely, Mark A Miller, Thomas J Louie, Derrick W Crook, Sherwood L Gorbach, Oliver A Cornely, Mark A Miller, Thomas J Louie, Derrick W Crook, Sherwood L Gorbach

Abstract

Recurrence of Clostridium difficile infection (CDI) occurs in approximately 25% of successfully treated patients. Two phase 3 randomized, double-blind trials were conducted at 154 sites in the United States, Canada, and Europe to compare fidaxomicin vs vancomycin in treating CDI. Patients with CDI received fidaxomicin 200 mg twice daily or vancomycin 125 mg 4 times daily for 10 days. The primary end point was clinical cure of CDI at end of treatment, and a secondary end point was recurrence during the 28 days following clinical cure. In all, 1164 subjects were enrolled, of which a subgroup of 128 in the per-protocol population had another recent episode of CDI prior to the CDI diagnosis at study enrollment. In the analysis of this subgroup, initial response to therapy was similar for both drugs (>90% cure). However, recurrence within 28 days occurred in 35.5% of patients treated with vancomycin and 19.7% of patients treated with fidaxomicin (-15.8% difference; 95% confidence interval, -30.4% to -0.3%; P = .045). Early recurrence (within 14 days) was reported in 27% of patients treated with vancomycin and 8% of patients treated with fidaxomicin (P = .003). In patients with a first recurrence of CDI, fidaxomicin was similar to vancomycin in achieving a clinical response at end of therapy but superior in preventing a second recurrence within 28 days.

Trial registration: ClinicalTrials.gov NCT00314951 NCT00468728.

Figures

Figure 1.
Figure 1.
Disposition of patients. Patients could have >1 reason for exclusion from an analysis population. Abbreviations: BID, twice daily; CDI, Clostridium difficile infection; mITT, modified intent to treat; QID, 4 times daily.
Figure 2.
Figure 2.
Time to recurrence by treatment group in patients with a prior episode of Clostridium difficile infection. Kaplan–Meier analysis of the probability of recurrence according to treatment group (per-protocol population). Day 0 is defined as the day the patient received the last dose of either fidaxomicin or vancomycin. The difference between treatment groups was statistically significant by both log rank (P = .02) and Wilcoxon (P = .01) tests.
Figure 3.
Figure 3.
Time to recurrence by age group in patients with a prior episode of Clostridium difficile infection. Kaplan–Meier analysis of the probability of recurrence according to age group (per-protocol population). Day 0 is defined as the day the patient received the last dose of either fidaxomicin or vancomycin. The difference between age groups was statistically significant by both log rank (P = .006) and Wilcoxon (P = .01) tests.

References

    1. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect. 2009;58:403–10.
    1. Baines SD, O'Connor R, Saxton K, Freeman J, Wilcox MH. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother. 2009;63:520–5.
    1. Freeman J, Baines SD, Saxton K, Wilcox MH. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. J Antimicrob Chemother. 2007;60:83–91.
    1. Louie TJ, Emery J, Krulicki W, Byrne B, Mah M. OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother. 2009;53:261–3.
    1. Wilson KH. The microecology of Clostridium difficile. Clin Infect Dis. 1993;16(Suppl 4):S214–8.
    1. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis. 2003;36:580–5.
    1. van Nood E, Speelman P, Kuijper EJ, Keller JJ. Struggling with recurrent Clostridium difficile infections: is donor faeces the solution? Euro Surveill. 2009;14:pii 19316.
    1. Yoon SS, Brandt LJ. Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients. J Clin Gastroenterol. 2010;44:562–6.
    1. Bauer MP, Kuijper EJ, van Dissel JT European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI) Clin Microbiol Infect. 2009;15:1067–79.
    1. Cohen SH, Gerding DN, Johnson S, et al. Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) Infect Control Hosp Epidemiol. 2010;31:431–55.
    1. Miller M. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection. Expert Opin Pharmacother. 2010;11:1569–78.
    1. Poxton IR. Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections. Future Microbiol. 2010;5:539–48.
    1. Sullivan KM, Spooner LM. Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection. Ann Pharmacother. 2010;44:352–9.
    1. Shah D, Dang MD, Hasbun R, et al. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Antiinfect Ther. 2010;8:555–64.
    1. Louie TJ, Miller MA, Mullane KM, et al. OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422–31.
    1. Sears PS, Crook DW, Louie TJ, Miller M, Weiss K. High fecal and low plasma levels of fidaxomicin and metabolite OP-1118 in patients with C. difficile infections: combined results of two phase 3 trials [poster Mo1160] Program and abstracts of Digestive Disease Week Chicago). Bethesda, MD: DDW, 2011.
    1. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile–associated diarrhea. J Infect Dis. 2008;197:435–8.
    1. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001;357:189–93.
    1. Johnson S, Adelmann A, Clabots CR, Peterson LR, Gerding DN. Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. J Infect Dis. 1989;159:340–3.
    1. Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit JC. Epidemiology of recurrences or reinfections of Clostridium difficile–associated diarrhea. J Clin Microbiol. 2000;38:2386–8.
    1. Pépin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile–associated disease in Quebec, Canada. Clin Infect Dis. 2006;42:758–64.
    1. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40:1591–7.
    1. Tannock GW, Munro K, Taylor C, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile–infected patients than does vancomycin. Microbiology. 2010;156:3354–9.
    1. Bauer MP, van Dissel JT, Kuijper EJ. Clostridium difficile: controversies and approaches to management. Curr Opin Infect Dis. 2009;22:517–24.
    1. Al-Nassir WN, Sethi AK, Li Y, Pultz MJ, Riggs MM, Donskey CJ. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile–associated disease. Antimicrob Agents Chemother. 2008;52:2403–6.
    1. Nerandzic MM, Mullane K, Miller M, Babakhani F, Donskey CJ. Acquisition and overgrowth of vancomycin-resistant enterococci in patients treated with either fidaxomicin (FCX) or vancomycin (VAN) for Clostridium difficile infection [abstract K-1915] 2009 In: Program and abstracts of the 49th ICAAC (Washington, DC). Washington, DC: ICAAC.
    1. Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev. 2008;1:CD004611.
    1. Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile–associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis. 2007;44:846–8.
    1. Curry SR, Marsh JW, Shutt KA, et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis. 2009;48:425–9.
    1. Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother. 2007;51:2716–9.
    1. O'Connor JR, Galang MA, Sambol SP, et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother. 2008;52:2813–7.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel